Australia - English - Department of Health (Therapeutic Goods Administration)

theramex australia pty ltd - 44127 - needle, injector, medication/vaccine - a sharply pointed needle used to penetrate the skin to deliver medicine to a patient. the device is only for single use.

European Union - English - EMA (European Medicines Agency)

theramex ireland limited - teriparatide - osteoporosis - calcium homeostasis - livogiva is indicated in adults.treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated.treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.

Australia - English - Department of Health (Therapeutic Goods Administration)

theramex australia pty ltd - 44127 - needle, injector, medication/vaccine - for the administration of ovaleap from a cartridge in one of 3 strengths (300iu/450iu or 900iu). the procedure pack also contains either 10 needles (300iu and 450iu packs) or 20 needles (900iu pack). for use with the ovaleap pen.

Australia - English - Department of Health (Therapeutic Goods Administration)

theramex australia pty ltd - 45771 - cartridge-accepting autoinjector, mechanical - ovaleap pen is for self-injection of a desired dose of ovaleap. injection is achieved by loading the desired cartridge of ovaleap and attaching diposable pen needle. this is a reusable device.

European Union - English - EMA (European Medicines Agency)

theramex ireland limited - linzagolix choline - leiomyoma - pituitary and hypothalamic hormones and analogues - yselty is indicated for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.

European Union - English - EMA (European Medicines Agency)

theramex ireland limited - abaloparatide - osteoporosis, postmenopausal; osteoporosis - calcium homeostasis - treatment of osteoporosis in postmenopausal women at increased risk of fracture.